Evommune (EVMN) Earnings Analysis

Evommune (EVMN) next reports earnings on 2026-10-16, consensus EPS -0.82 USD. Last quarter (2026-05-07) it beat with EPS -0.64 USD vs -0.83 USD est (+22.9%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E -4.77.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does EVMN next report earnings?

Next earnings date2026-10-16
Consensus EPS estimate-0.82 USD
Revenue estimate0.00B

EVMN earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.64 USD-0.83 USD+22.9%Beat
2026-03-05-1.43 USD-0.82 USD-74.4%Miss
2025-12-11-8.07 USD-6.08075 USD-32.7%Miss

Beat rate: 1/3 (33%) over reported quarters with consensus data.

EVMN valuation and analyst view

Trailing P/E-4.77
Trailing EPS-2.25681 USD
Price / book1.26
Dividend yield0.00%
Market cap0.16B
Analyst consensusBuy (2 buy / 2 hold / 0 sell)
Avg price target43.67 USD

Related research pages

Frequently asked questions

When is Evommune (EVMN)'s next earnings date?

Evommune is next scheduled to report on 2026-10-16, with a consensus EPS estimate of -0.82 USD and revenue estimate of 0.00B.

Did EVMN beat earnings last quarter?

In its 2026-05-07 report, EVMN posted EPS of -0.64 USD versus a -0.83 USD estimate — a beat of 22.9%.

What is EVMN's earnings track record?

Over the last 3 reported quarters with consensus data, EVMN beat estimates 1 times (33%).

What is EVMN's current P/E ratio and EPS?

EVMN trades at a trailing P/E of -4.77 on trailing EPS of -2.2568062367887425 USD.

What do analysts rate EVMN?

Analyst consensus is "Buy" across 4 ratings (0 strong buy, 2 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 43.67 USD.